On May 24, 2022, Coala Life will publish its report for the first quarter of 2022. On the same day at 09.00 CEST, investors, analysts and journalists are invited to a webcast where CEO Dan Pitulia presents the report and latest updates from the market followed by a question-and-answer session led by Erik Nordström, analyst at Redeye. The presentation can be viewed via the following link: https://www.redeye.se/events/840265/live-q-coala-life
About us
Coala Life is a medical device company founded in Sweden focusing on cloud-based cardiac and pulmonary diagnostics. The company has developed and launched the Coala Heart Monitor - a multi-award winning, FDA-cleared and CE-approved product platform enabling long-term remote monitoring, analysis and algorithm-based diagnostics of heart and auscultation of lungs, remote in real-time. The Coala Heart Monitor is mainly marketed to healthcare providers as an Rx solution for use in patient’s everyday life and home environment. The company's solutions are based on over 10 years of R&D, and are protected by more than 30 patents. The head office is based in Uppsala, Sweden and since 2019, the US office is based in Irvine, California. More than 10,000 patients have used, been diagnosed or are under long-term monitoring with the Coala Heart Monitor. In the Coala Care Portal, there are currently more than 1,700 doctors and nurses connected to more than 500 care providers. For more information see www.coalalife.com
For more information, contact:
Dan Pitulia, CEO Coala Life AB
+46 70 972 08 38, dan.pitulia@coalalife.com
Philip Siberg, Co-founder, Chief Strategy Officer and Head of IR
+46 70 790 67 34, philip.siberg@coalalife.com
Certified Adviser
The company's Certified Adviser is Erik Penser Bank AB.
Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm,
tel: +46 (0) 8-463 80 00
email: certifiedadviser@penser.se